Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00467181 |
| Other study ID # |
RP05009 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 2
|
| First received |
April 26, 2007 |
| Last updated |
January 28, 2008 |
| Start date |
January 2005 |
| Est. completion date |
April 2006 |
Study information
| Verified date |
April 2007 |
| Source |
Summa Health System |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
United States: Institutional Review Board |
| Study type |
Interventional
|
Clinical Trial Summary
The Primary objective is to reduce the incidence of postoperative renal dysfunction in a
high-risk subset of patients undergoing cardiac surgery on cardiopulmonary bypass with
Fenolopam, a selective dopamine-1 receptor agonist. Perioperative renal function will be
observed in 3 randomly selected groups of patients-Fenoldopam infusion at 0.03 cg/kg/min,
Fenoldopam at 0.1 mcg/kg/min or placebo
Secondary objective: will be to correlate Fenoldopam usage with postoperative clinical
outcomes such as ICU stay, hospital stay, need for inotropes/vasopressors, need for
diuretics, requirements for ECF at discharge, and overall perioperative cost reduction
through decreased ICU and hospital length of stay.
Description:
Although all patients undergoing cardiac surgery are at risk for renal dysfunction, there
are certain preoperative clinical parameters which have been shown to place patients at
particularly high risk for postoperative renal demise. These factors include age greater
than 70 (with those patients greater than 80 years being at particular high risk), history
of New York Heart Association Class 3 or 4 congestive heart failure, previous coronary
artery bypass grafting, pre-operative creatinine level 1.24-1.77 mmol/dL, type I diabetes,
preoperative glucose >166 mmol/dL, cardiopulmonary bypass time >3 hours, and low cardiac
output states (those states requiring intra-aortic balloon pump (IABP) or with cardiac index
of less than 1.5 or requiring more than 3 inotropic drugs).1 Recently, there has been
interest in the pharmacologic manipulation of peripheral dopamine receptors (DA1 and DA2) in
an attempt to augment and preserve renal function. Goldberg and colleagues localized DA1
receptors to vascular smooth muscle postsynaptic membranes in renal, coronary, cerebral,
mesenteric, and peripheral artery vasculature, in the proximal convoluted tubule, and in the
cortical collecting ducts of the nephron.6,7 Stimulation of the DA1 receptor activates
adenylate cyclase causing vascular smooth muscle vasodilation and naturesis with increased
urinary sodium excretion by inhibiting sodium-potassium ATPase-dependent processes at the
proximal convoluted tubule and the thick portion of the ascending loop of Henle.6,8,9 The
greatest effect of DA1 receptor activation occurs in the renal vasculature (mostly at
afferent arteriole)9, causing an increase of renal blood flow up to 35% in normal patients
and up to 77% in those patients with renal vascular disease.10,11 DA2 receptors are found in
the renal parenchyma, presynaptic nerve terminals of adrenergic nerves and sympathetic
ganglia, and in the adrenal cortex.10 DA2 receptor activation leads to inhibition of
norepinephrine release (as part of a negative feedback loop) and inhibition of angiotensin
II mediated release of aldosterone.10,12 With activation of DA2 receptors in the kidney, a
resultant decrease in renal blood flow, decrease in glomerular filtration rate, and decrease
in diuresis and naturesis is observed, effects that are opposite to and may offset DA-1
receptor agonism. Mayes and colleagues showed no improvement in renal function in patient
undergoing CABG with "renal-dose" dopamine.6, 13 It is theorized that dopamine's inability
to provide renal protection may be due to its lack of specificity for DA-1 receptors and
resultant dose-dependent agonism for DA-2 receptors and alpha1-adrenergic receptors.6, 14,
15 As mentioned, dopamine's activation of these receptors results in decreased renal blood
flow, glomerular filtration rate, and sodium excretion6, 16, thereby offsetting the effects
of DA-1 receptor agonism.
Fenoldopam is the first commercially available selective DA1 receptor agonist. Fenoldopam is
a selective agonist for DA1 receptors with no activity at DA2 receptors, alpha adrenergic
receptors, or beta adrenergic receptors. Currently, Fenoldopam is used as an intravenous
infusion for hypertensive emergencies. When given to hypertensive patients in doses of
0.025-0.5 mcg/kg/min, a reduction in blood pressure is seen in a linear and dose dependent
manner.9, 17, 18, 19, 20 Despite reductions in perfusion pressure, glomerular filtration
rate and renal blood flow are equivalent or even increased.9, 20, 21 When given to
normotensive patients at doses of 0.03-0.3 mcg/kg/min, Vandana and colleagues have shown
that Fenoldopam significantly increased renal blood flow in a dose-dependent manner when
compared with placebo with no change in systolic blood pressure and minimal changes in
diastolic blood pressure (1 mmHg @ 0.3 mcg/kg/min dose) and heart rate (14 bpm @ 0.3
mcg/kg/min dose). In addition, there were no serious or severe side effects even at the
highest doses.9 These observations are consistent with prior studies of Fenoldopam in both
normotensive22 and hypotensive23 patients. Fenoldopam's lack of effects on venous
capacitance as well as the lesser role that resistance plays in determining blood pressure
in normotensive patients may further explain the negligible effect that Fenoldopam has on
blood pressure in normotensive subjects. This leads to a theoretic "renal protection"
provided by Fenoldopam at doses which elicit negligible deleterious effects.
As mentioned, Fenoldopam is a selective DA1 receptor agonist created through modification of
the dopamine molecule with the addition of chloride, sulfur, and a benzene ring.10 These
changes result in agonistic effects exclusively on the DA-1 receptor with no DA2 receptor
activation and no direct or indirect actions on both alpha and beta adrenergic receptors.10
Fenoldopam has a short half-life of 5-10 minutes, a linear relationship between plasma
concentration and infusion rate, and a small volume of distribution allowing rapid
intravenous titration.24 These characteristics make Fenoldopam ideal for intravenous
infusion with a steady-state plasma concentration being achieved within 30-60 minutes,
steady-state concentrations remaining constant during infusion, and with a negligible
concentration (<0.2 mcg/L) 2 hours after discontinuation as demonstrated by Allison and
colleagues.24 Hepatic clearance of Fenoldopam occurs through conjugation via sulfation or
glucuronidation.10 Klecker and colleagues demonstrated that drug-drug interactions are
negligible due to parallel pathways of metabolism.25 Recent studies by Garwood and
colleagues and Caimmi and colleagues have shown preservation of renal function by
perioperative infusion of Fenoldopam as indicated by lower creatinine level at discharge in
those patients at high risk for perioperative renal demise.26, 27 However, a prospective
randomized control trial has yet to be performed. There is also uncertainty that these
reductions in serum creatinine levels at discharge are of any practical benefit in terms of
reduced morbidity, reduced length of stay, reduced cost, or improved clinical performance.
In addition, an optimal dose for Fenoldopam for this clinical indication has yet to be
determined. For this pilot study, Fenoldopam will be infused at 0.03 mcg/kg/min or 0.1
mcg/kg/min. These doses were chosen due to their proven effectiveness to significantly
increase renal blood flow with minimal effects on blood pressure and heart rate.9 The goal
of this study is to evaluate the effectiveness of Fenoldopam, a new selective dopamine-1
receptor agonist, in the reduction of postoperative renal dysfunction in a high-risk subset
of patients undergoing cardiac surgery in a prospective randomized control pilot study. This
will be accomplished through infusion of Fenoldopam at 0.03 mcg/kg/min, 0.1 mcg/kg/min, or
placebo in a double blinded, randomized, prospective trial where postoperative creatinine,
urine output, and progression to renal dysfunction will be observed. Renal dysfunction will
be defined as an increase in serum creatinine by greater than 50% of the preoperative value
or a serum creatinine that exceeds 2.0 mg/dL at any time postoperatively prior to
discharge.. In addition, length of ICU stay, length of hospital stay, ventilator
requirements, need for diuretics, need for perioperative inotropes/vasopressors, and need
for discharge to extended care facilities will be examined for each group. The null
hypothesis is that Fenoldopam will not reduce the incidence of postoperative renal
dysfunction.
